Kanawha Capital Management LLC Purchases 435 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Kanawha Capital Management LLC raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 25.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,178 shares of the medical equipment provider’s stock after purchasing an additional 435 shares during the period. Kanawha Capital Management LLC’s holdings in Zimmer Biomet were worth $236,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. OLD Point Trust & Financial Services N A bought a new position in Zimmer Biomet in the 4th quarter valued at $26,000. Ables Iannone Moore & Associates Inc. bought a new position in Zimmer Biomet in the 4th quarter valued at $30,000. Crewe Advisors LLC bought a new position in Zimmer Biomet in the 1st quarter valued at $31,000. Family Firm Inc. purchased a new stake in shares of Zimmer Biomet during the 2nd quarter valued at $33,000. Finally, J.Safra Asset Management Corp raised its position in shares of Zimmer Biomet by 712.1% during the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 235 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Analyst Ratings Changes

ZBH has been the topic of several research reports. Canaccord Genuity Group lowered their price objective on shares of Zimmer Biomet from $130.00 to $120.00 and set a “hold” rating on the stock in a research report on Tuesday, August 20th. Piper Sandler cut shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $140.00 to $115.00 in a research report on Monday, July 1st. Barclays lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a research report on Friday, May 31st. Truist Financial lowered their price objective on shares of Zimmer Biomet from $130.00 to $117.00 and set a “hold” rating on the stock in a research report on Tuesday, July 16th. Finally, Evercore ISI lowered their price objective on shares of Zimmer Biomet from $115.00 to $113.00 and set an “in-line” rating on the stock in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $127.11.

Zimmer Biomet Trading Up 1.4 %

Shares of ZBH stock traded up $1.63 during mid-day trading on Friday, reaching $115.05. The stock had a trading volume of 788,447 shares, compared to its average volume of 1,388,773. The stock’s 50-day moving average price is $108.98 and its two-hundred day moving average price is $117.67. The firm has a market capitalization of $23.67 billion, a PE ratio of 24.90, a price-to-earnings-growth ratio of 2.02 and a beta of 1.01. The company has a current ratio of 1.29, a quick ratio of 0.63 and a debt-to-equity ratio of 0.31. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.02. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.82 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.06 earnings per share for the current fiscal year.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.